28:1332 Diversity-Product Liability
A Pennsylvania federal judge on Tuesday rejected Santa Clara County, California's efforts to dismiss its false advertising claims from multidistrict litigation over GlaxoSmithKline PLC’s diabetes medication Avandia in order to refile them in state court, ruling the federal courts correctly took jurisdiction when the county filed suit five years ago.
GlaxoSmithKline PLC told a Pennsylvania federal court Thursday that third-party payors in multidistrict litigation alleging the company misrepresented the safety of its Avandia diabetes drugs are now claiming for the first time and with no supporting evidence that GSK promised Avandia had cardiovascular benefits.
Third-party payor United Benefit Fund told a Pennsylvania federal court on Friday that it should not be punished with sanctions for seeking to leave a class action alleging GlaxoSmithKline LLC misrepresented the safety of its Avandia diabetes drugs, pointing to evidence that its claims had merit and were not baseless.
GlaxoSmithKline LLC asked a Pennsylvania federal court on Wednesday to sanction two third-party payors that recently asked to drop their class actions against GSK over the safety of its Avandia diabetes drugs, saying they should be punished for pursuing claims for years without the evidence to back them up.
Third-party payors in a class action alleging GlaxoSmithKline LLC misrepresented the safety of its Avandia diabetes drugs told a Pennsylvania federal judge on Thursday that the pharmaceutical company is distorting what they’re actually claiming.
United Benefit Fund, one of four payors who filed a class action alleging GlaxoSmithKline LLC misrepresented the safety of its Avandia diabetes drugs, took one for the team Friday and asked a Pennsylvania federal court to kill its own claims for a faster resolution.
A Pennsylvania federal judge has ruled that the lead plaintiff in a proposed class action rolled into multidistrict litigation covering claims that GlaxoSmithKline LLC concealed dangerous side effects of its diabetes drug Avandia failed to show that she was harmed in any way.
GlaxoSmithKline LLC on Monday asked the Third Circuit to toss racketeering claims in three class actions accusing the drugmaker of hiding heart disease risks associated with the diabetes drug Avandia, arguing the plaintiffs haven’t alleged a clearly identifiable injury.
Girardi Keese said Tuesday that it will appeal to the Third Circuit to fight a May order requiring GlaxoSmithKline to hold back 7 percent of the gross recovery from all Girardi cases in the sprawling Avandia product liability multidistrict litigation.
A Pennsylvania district judge dismissed 115 out of 117 cases that GlaxoSmithKline LLC argued were outside the statute of limitations in the multidistrict litigation over injuries caused by diabetes drug Avandia, ruling Friday that the cases were clearly untimely.